Valuation: Virbac

Market Cap 2.87B 3.27B 2.64B 2.47B 4.64B 308B 4.72B 31.72B 12.29B 152B 12.27B 12B 528B P/E 2026 *
17.1x
P/E 2027 * 15.2x
Enterprise Value 2.99B 3.4B 2.76B 2.58B 4.83B 321B 4.92B 33.06B 12.8B 158B 12.78B 12.5B 550B EV / Sales 2026 *
1.93x
EV / Sales 2027 * 1.77x
Free-Float
49.03%
Yield 2026 *
0.51%
Yield 2027 * 0.6%
1 day+1.04%
1 week+1.21%
Current month-6.68%
1 month-6.28%
3 months-4.14%
6 months-4.01%
Current year-3.73%
1 week 329
Extreme 329
338.5
1 month 323
Extreme 323
362.5
Current year 322
Extreme 322
381
1 year 297
Extreme 297
381
3 years 237.5
Extreme 237.5
392
5 years 220.5
Extreme 220.5
440.5
10 years 102.48
Extreme 102.479
440.5
Manager TitleAgeSince
Chief Executive Officer 46 01/09/2025
Chief Executive Officer 50 27/09/2024
Chief Operating Officer 64 01/01/2022
Director TitleAgeSince
Chairman 61 01/04/2006
Director/Board Member 68 28/07/2010
Director/Board Member 65 05/09/2017
Change 5-day change 1-year change 3-year change Capi.($)
+1.04%+1.21% - - 3.27B
-0.45%-1.13%-50.51%-53.78% 32.62B
+1.71%+0.62%+77.11%+148.17% 12.17B
-2.48%-5.64%-6.22%+16.05% 4.1B
-1.71%+2.63%+49.50%+30.45% 1.94B
+1.41%+3.08%-23.28%-1.79% 1.64B
+1.50%-0.06%+28.61%+136.30% 1.29B
-1.85%-2.50%-23.25%-16.55% 990M
-0.83%+2.89%-2.33%-18.05% 951M
-2.59%-5.35%-17.19%-48.63% 905M
Average -0.42%-0.55%+3.60%+21.35% 6.29B
Weighted average by Cap. -0.08%-0.83%-12.02%+4.76%

Financials

2026 *2027 *
Net sales 1.55B 1.76B 1.42B 1.33B 2.5B 166B 2.54B 17.09B 6.62B 81.89B 6.61B 6.47B 285B 1.64B 1.87B 1.51B 1.41B 2.65B 176B 2.7B 18.12B 7.02B 86.82B 7.01B 6.86B 302B
Net income 167M 190M 154M 144M 270M 17.94B 275M 1.85B 715M 8.84B 714M 698M 30.74B 190M 217M 175M 164M 307M 20.43B 313M 2.1B 814M 10.07B 813M 795M 35B
Net Debt 121M 138M 111M 104M 195M 13B 199M 1.34B 518M 6.41B 517M 506M 22.27B 26.49M 30.16M 24.41M 22.82M 42.8M 2.85B 43.59M 293M 113M 1.4B 113M 111M 4.88B
Logo Virbac
Virbac specializes in the research, production and marketing of veterinary medicines. Net sales break down by family of products as follows: - pet medications (60.7%): pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds, rodents, etc. The group also offers foods and electronic identification chips; - livestock medications (39.3%): pest control drugs and antibiotics intended for cattle, sheep, pigs, poultry, etc. Net sales are distributed geographically as follows: Europe (41.6%), Latin America (15.2%), North America (13.6%), India/Africa/Middle East (12.2%), Eastern Asia (10.5%) and Pacific (6.9%).
Employees
6,442
Date Price Change
26/06/26 EUR 335.50 -0.74%
25/06/26 EUR 338.00 +1.20%
24/06/26 EUR 334.00 +0.60%
23/06/26 EUR 332.00 -0.30%
22/06/26 EUR 333.00 +0.45%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
342.50EUR
Average target price
412.88EUR
Spread / Average Target
+20.55%

Quarterly revenue - Rate of surprise